Table 3.

Treatment-related adverse events.

	HER2-low (N = 144)		HER2-positive (N = 173)		Overall (N = 317)
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
Any AE	117 (81.3%)	32 (22.2%)	149 (86.1%)	35 (20.2%)	266 (83.9%)	67 (21.1%)
SAE	17 (11.8%)	17 (11.8%)	15 (8.7%)	15 (8.7%)	32 (10.1%)	32 (10.1%)
Leukopenia	57 (39.6%)	14 (9.7%)	51 (29.5%)	6 (3.5%)	108 (34.1%)	20 (6.3%)
Neutropenia	51 (35.4%)	14 (9.7%)	44 (25.4%)	12 (6.9%)	95 (30.0%)	26 (8.2%)
Anemia	51 (35.4%)	6 (4.2%)	60 (34.7%)	4 (2.3%)	111 (35.0%)	10 (3.2%)
Thrombocytopenia	19 (13.2%)	5 (3.5%)	27 (15.6%)	4 (2.3%)	46 (14.5%)	9 (2.8%)
Nausea	42 (29.2%)	2 (1.4%)	44 (25.4%)	2 (1.2%)	86 (27.1%)	4 (1.3%)
Dyspepsia	33 (22.9%)	1 (0.7%)	42 (24.3%)	3 (1.7%)	75 (23.7%)	4 (1.3%)
Vomit	23 (16.0%)	3 (2.1%)	31 (17.9%)	2 (1.2%)	54 (17.0%)	5 (1.6%)
Fatigue	18 (12.5%)	2 (1.4%)	19 (11.0%)	4 (2.3%)	37 (11.7%)	6 (1.9%)
Pneumonia	18 (12.5%)	6 (4.2%)	16 (9.2%)	6 (3.5%)	34 (10.7%)	12 (3.8%)
Interstitial lung disease	16 (11.1%)	7 (4.9%)	13 (7.5%)	8 (4.6%)	29 (9.1%)	15 (4.7%)
Peripheral sensory neuropathy	8 (5.6%)	0	20 (11.6%)	1 (0.6%)	28 (8.8%)	1 (0.3%)
Dizziness	12 (8.3%)	0	13 (7.5%)	1 (0.6%)	25 (7.9%)	1 (0.3%)
Headache	11 (7.6%)	2 (1.4%)	10 (5.8%)	2 (1.2%)	21 (6.6%)	4 (1.3%)
Constipation	7 (4.9%)	0	9 (5.2%)	0	16 (5.0%)	0
Diarrhea	8 (5.6%)	2 (1.4%)	3 (1.7%)	0	11 (3.5%)	2 (0.6%)
Rash	3 (2.1%)	0	5 (2.9%)	0	8 (2.5%)	0
Oral ulcer	2 (1.4%)	0	5 (2.9%)	0	7 (2.2%)	0
Pruritus	2 (1.4%)	0	1 (0.6%)	0	3 (0.9%)	0
AST elevation	32 (22.2%)	1 (0.7%)	53 (30.6%)	3 (1.7%)	85 (26.8%)	4 (1.3%)
ALT elevation	21 (14.6%)	1 (0.7%)	42 (24.3%)	0	63 (19.9%)	1 (0.3%)
Hypoalbuminemia	28 (19.4%)	0	44 (25.4%)	0	72 (22.7%)	0
Serum total bilirubin elevation	12 (8.3%)	1 (0.7%)	13 (7.5%)	1 (0.6%)	25 (7.9%)	2 (0.6%)
Serum Creatinine elevation	8 (5.6%)	0	13 (7.5%)	0	21 (6.6%)	0

Abbreviation: HER2, human epidermal growth factor receptor 2